Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients;Farmacocinética poblacional de gemcitabina aplicada a la personalización de su dosificación en pacientes oncológicos

Farmacia Hospitalaria

Volumn 36, Issue 4, 2012, Pages 194-206

  Ramon Lopez A ^a   Escudero Ortiz, V ^b   Duart Duart, M J ^a   Perez Ruixo J J ^c   Valenzuela, B ^b  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b USP Hospital San Jaime   (Spain)

^c Farmacia Hospitalaria   (Spain)

Author keywords

Bayesian population analysis; dFdU; Gemcitabine; NONMEM; Oncology; Pharmacokinetics; Pharmacotherapy optimisation

Indexed keywords

2',2' DIFLUORODEOXYURIDINE; DRUG METABOLITE; GEMCITABINE; UNCLASSIFIED DRUG;

ACCURACY; ARTICLE; BAYES THEOREM; BOOTSTRAPPING; CANCER PAIN; CLINICAL ARTICLE; COMPARTMENT MODEL; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; INTERNAL VALIDITY; NONPARAMETRIC TEST; PERSONALIZED MEDICINE; POPULATION RESEARCH; PREDICTIVE VALIDITY; STEADY STATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; FLOXURIDINE; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; NEOPLASMS; REPRODUCIBILITY OF RESULTS; YOUNG ADULT;

EID: 84865462960     PISSN: 11306343     EISSN: 21718695     Source Type: Journal    
DOI: 10.1016/j.farma.2011.04.002     Document Type: Article

References (29)

1. E. Mini, S. Nobili, B. Caciagli, I. Landini, and T. Mazzei Cellular pharmacology of gemcitabine Ann Oncol 17 Suppl 5 2006 v7 v12
2. P. Huang, S. Chubb, L.W. Hertel, G.B. Grindey, and W. Plunkett Action of 2',2'-difluorodeoxycytidine on DNA synthesis Cancer Res 51 1991 6110 6117
3. V.W. Ruiz van Haperen, G. Veerman, J.B. Vermorken, and G.J. Peters 2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Biochem Pharmacol 46 1993 762 766
4. C.H. Baker, J. Banzon, J.M. Bollinger, J. Stubbe, V. Samano, and M.J. Robins 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase J Med Chem 34 1991 1879 1884
5. V. Heinemann, L. Schulz, R.D. Issels, and W. Plunkett Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism Semin Oncol 22 1995 11 18
6. V. Heinemann, Y.Z. Xu, S. Chubb, A. Sen, L.W. Hertel, and G.B. Grindey Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation Cancer Res 52 1992 533 539
7. P. Pourquier, C. Gioffre, G. Kohlhagen, Y. Urasaki, F. Goldwasser, and L.W. Hertel Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I Clin Cancer Res 8 2002 2499 2504
8. Ficha técnica de Gemcitabina. Agencia Española de Medicamentos y Productos Sanitarios. Madrid: Ministerio de Sanidad y Consumo; 2008.
9. K.B. Freeman, S. Anliker, M. Hamilton, D. Osborne, P.H. Dhahir, and R. Nelson Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection J Chromatogr B 665 1995 171 181
10. E. Sugiyama, N. Kaniwa, S.R. Kim, R. Hasegawa, Y. Saito, and H. Ueno Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms Clin Pharmacokinet 49 2010 549 558
11. E. Poplin, Y. Feng, J. Berlin, M.L. Rothenberg, H. Hochster, and E. Mitchell Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group J Clin Oncol 27 2009 3778 3785
12. R. Grunewald, J.L. Abbruzzese, P. Tarassoff, and W. Plunkett Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine Cancer Chemother Pharmacol 27 1991 258 262
13. A.M. Storniolo, S.R. Allerheiligen, and H.L. Pearce Preclinical, pharmacologic, and phase I studies of gemcitabine Semin Oncol 24 1997 S72 S77
14. M. Tempero, W. Plunkett, V. Ruiz Van Haperen, J. Hainsworth, H. Hochster, and R. Lenzi Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma J Clin Oncol 21 2003 3402 3408
15. F. Cappuzzo, S. Novello, F. De Marinis, G. Selvaggi, G.V. Scagliotti, and F. Barbieri A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy Lung Cancer 52 2006 319 325
16. X. Jiang, P. Galettis, M. Links, P.L. Mitchell, and A.J. McLachlan Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate Br J Clin Pharmacol 65 2008 326 333
17. L.S. Tham, L.Z. Wang, R.A. Soo, H.S. Lee, S.C. Lee, and B.C. Goh Does saturables formation of gemcitabine triphosphate occur in patients? Cancer Chemother Pharmacol 63 2008 55 64
18. L.S. Tham, L. Wang, R.A. Soo, S.C. Lee, H.S. Lee, and W.P. Yong A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients Clin Cancer Res 14 2008 4213 4218
19. B. Porta, J.J. Pérez-Ruixo, N.V. Jiménez, A. Sancho, and L.M. Pallardó Individualización posológica de ciclosporina en pacientes con trasplante renal: propuesta de un modelo farmacocinético de predicción Farm Hosp 22 1998 181 187
20. Escudero-Ortiz V, Duart-Duart MJ, Pérez-Ruixo JJ, Valenzuela B. Determinación de gemcitabina y su metabolito, 2',2'-difluorodeoxiuridina, en plasma humano mediante HPLC. Rev. OFIL 2011, 21;3:103-12.
21. Beal SL, Sheiner LB, Boeckman AJ, editores. NONMEN users guides. Ellicott City: ICON Development Solutions; 1989-2006.
22. Y. Wang Derivation of various NONMEM Estimation methods J Pharmacokinet Pharmacodyn 34 2007 575 593
23. J.E. Ahn, M.O. Karlsson, A. Dunne, and T.M. Ludden Likelihood based approaches to handling data below the quantification limit using NONMEM VI J Pharmacokinet Pharmacodyn 35 2008 401 421
24. S.L. Beal Ways to fit model with some data below the quantification limit J Pharmacokinet Pharmacodyn 28 2001 481 504
25. P.O. Gisleskog, M.O. Karlsson, and S.L. Beal Use of prior information to stabilize a population data analysis J Pharmacokinet Pharmacodyn 29 2002 473 505
26. L.B. Sheiner, and S.L. Beal Some suggestions for measuring predictive performance J Pharmacokinetic Biopharm 9 1981 503 512
27. V. Duval, and M.O. Karlsson Impact of omission or replacement of data below the limit of quantification on parameter estimates in a two-compartment model Pharm Res 19 2002 1835 1840
28. V. Mey, E. Giovannetti, F. De Braud, S. Nannizzi, G. Curigliano, and F. Verweij In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients Br J Cancer 95 2006 289 297
29. J. Matsubara, M. Ono, A. Negishi, H. Ueno, T. Okusaka, and J. Furuse Identification of a predictive biomerker for hematologic toxicities of gemcitabine J Clin Oncol 27 2009 2261 2268